Journal of Social Health and Diabetes / Vol 5 / Issue 1 / Jan-Jun 2017 such as immediate verbal recall, delayed verbal recall, and abstract reasoning. [5] However, conclusions vary depending on the sampling strategy, study design, tests for cognition used, diabetes severity, and co-existing morbidities. [6, 7] Several association pathways of T2DM and cognitive decline have been established whereby some studies reported the association of diabetes with Alzheimer's [8] and vascular dementia, [9] and other studies reported its association with hypertension [10] and stroke. [11] Another form, i.e., type 3 diabetes results with an insulin resistance in the brain causing Alzheimer's and has molecular and biochemical features encompassing both type 1 diabetes mellitus and T2DM. [12] Nevertheless, these studies have shown common manifestations of these pathways that contribute to cognitive impairment.
The possible link of T2DM with cognitive performance is intricate and remains unforeseen as other factors including age, socio-economic status, marital status, level of education, and other comorbidities also influence cognitive function. To understand the influence of diabetes on cognitive impairment, the present study was designed to examine the prevalence and predictors of neurocognitive impairment in type 2 diabetic population of Punjab, India.
Materials and Methods
The present cross-sectional study comprised 516 T2DM subjects who attended endocrinology outpatient department (OPD) of Government Medical College and Hospital (GMCH), Patiala, Punjab, India. A total of 1098 patients were screened and 1015 qualified for inclusion according to diagnostic criteria given by American Diabetes Association. [13] After following stringent inclusion-exclusion criteria, 516 diabetic subjects were included in the present research. The inclusion criterion was consenting T2DM patients belonging to Punjab. Exclusion criteria was subjects not from Punjab or had any other neurological conditions such as stroke, Alzheimer's disease, vascular dementia, Parkinson's disease, epilepsy or head injury, cardiovascular diseases such as hypertension, hypotension, or atherosclerosis and psychiatric disorders; depression, alcohol dependence, drug dependence, and use of antidepressant or antipsychotic medications [ Figure 1 ]. All patients gave their written consent prior to participation, and the study was approved by Institutional Ethical Committee.
Patients were assessed for cognitive impairment by using the Mini Mental State Examination (MMSE), [14] a standard version 30-point questionnaire used to screen arithmetic, language use, memory, and orientation (basic motor skills). It is a validated measure for evaluating cognitive decline, whereby MMSE score of <23 has sensitivity of 81.3% and specificity of 60.2%. [15] The scoring by MMSE can be influenced by the effect of age and education level. To avoid any bias, present data were well matched for age and education status (P > 0.05). Furthermore, other tests were Figure 1 : Showing data collection protocol after following stringent inclusion and exclusion criteria also used to screen subjects for cognitive decline such as trail making test-A (TMT-A for attention and information processing speed with visuomotor component) and trail making test-B (TMT-B for visual attention) [16] along with MMSE.
Definition of risk variables
Socio-economic status was evaluated according to the updated version of Kuppuswamy and Pareek scale [17] and categorized according to per capita per month income in rupees, ≤10,000 (low-income group), 10,000-50,000 (middle-income group), and >50,000 (high-income group). Physical activity was determined on the basis; if subject was doing at least 30 min of aerobic exercise/walk, he/she was considered active otherwise sedentary. Aerobic walking means consistent walk of 1 km in 13 min or less. Lipid levels, duration of diabetes, statin use, and glucose levels were noted down from their medical records. Information regarding marital status, education level, smoking, and drinking alcohol was recorded by interviewing them. Anthropometric measurements such as height and weight were measured and body mass index (BMI) was calculated according to Quetelet equation (BMI = weight in kilograms/height in meters squared). For waist-hip ratio, waist circumference was measured at the midpoint between the lower margin of ribs and the superior border of the iliac crest. Hip circumference was measured around the widest portion of the buttocks. Systolic blood pressure (SBP) and diastolic blood pressure were noted down as a mean of two tests conducted after an interval of 3 min in sitting position after 15 min of rest.
Statistical analysis
Data are presented as mean ± standard deviation, numbers or percentages, and interquartile range is given for skewed data. The difference between the groups was examined using Chi-square test for categorical variables and Student's t-test for continuous variables. The internal consistency reliability for MMSE, TMT-A, and TMT-B was checked using Cronbach's alpha. A linear regression was applied to investigate the association between cognitive decline and risk variables (general linear model procedure). Those variables which showed linear relationship with the dependent variable in univariate testing were further included in the multivariate logistic regression analysis (backward stepwise) to identify independent association of the significant variables. The significance was checked at 5% level, but for multiple comparisons, Bonferroni correction was applied accordingly.
Results
The present study involved 516 adult T2DM subjects of Punjab. Out of which, 289 (56.01%) were men and 227 (43.99%) were women. One hundred and seventy-four (33.73%) met the criteria for impaired cognition, whereas 342 (66.27%) were having normal cognition. The mean age of diabetic subjects was 47.79 ± 10.18. It is noteworthy that out of 174, 89.65% of the diabetic subjects were undiagnosed for neurocognitive impairment before participation in the present study. Univariate analysis of the variables [ Table 1 ] showed that women were approximately 2 times more vulnerable for cognitive (OR = 2.02, 95% CI: 1.36-2.99, P = 0.001), high-density lipoprotein (<40 mg/dl) (OR = 2.41, 95% CI: 1.59-3.64, P = 0.001), statin use (OR = 1.66, 95% CI: 1.15-2.34, P = 0.009), glucose levels (>125 mg/dl) (OR = 1.73, 95% CI: 1.20-2.50, P = 0.005), and duration of diabetes starting from 2 to 10 years and more than 10 years (P = 0.001) were having higher chances of cognitive impairment.
Multivariate backward stepwise regression analysis was done to identify variables which were independently associated with cognitive decline [ Table 2 ]. Being a woman (OR = 2.00, 95% CI: 1.25-3.20, P = 0.004), glucose levels >125 mg/dl (OR = 1.73, 95% CI: 1.15-2.61, P = 0.008), and SBP >120 mmHg (OR = 3.70, 95% CI: 2.40-5.60, P < 0.001) emerged as independent predictors of cognitive decline. Sedentary life style (OR = 2.32, 95% CI: 1.07-5.08, P = 0.034) and duration of diabetes >10 years (OR = 4.34, 95% CI: 2.57-7.29, P < 0.001) also conferred substantial risk of cognitive impairment independently.
Discussion
The present study examined the prevalence and predictors of neurocognitive impairment in T2DM patients of Punjab. This is the first study from this region which revealed that the prevalence of cognitive impairment is 33.73% in diabetic population. Being a diabetic woman is an independent risk factor for neurocognitive impairment which doubles the risk (OR = 2.13, 95% CI: 1.47-3.09, P < 0.001) as compared to man. This inference has been corroborated by some studies, [18, 19] and one study reported the risk of cognitive impairment even higher (3.75 times) in women. [20] The prevalence of neurocognitive impairment in T2DM has been scarcely examined in India. One study from Jaipur [21] has shown that the prevalence of neurocognitive impairment in T2DM patients is 48%, however, data from other regions have shown that cognitive decline in T2DM patients ranges from 3% to 23%. [22, 23] The prevalence rates of cognitive impairment may vary depending on the sampling procedure and diagnostic criteria. [24] Some of the reasons for higher prevalence of cognitive impairment in T2DM patients in the present study are, first of all, the diabetic OPDs of GMCH, Patiala, primarily caters to referred cases of severe form of diabetes. About 18% of the subjects in the present study have more than 10 years of diabetes, which may impinge upon the prevalence of cognitive impairment. Second, MMSE <23 criteria used in the present study also included subjects having borderline cognitive impairment (19-23 scores) . Such borderline subjects may also have supplemented the prevalence in the present study. Other tests (TMT-A and TMT-B) also identify neurocognition in those patients, and Cronbach's statistics in the present study (α = 0.82) ruled out any internal inconsistency.
The relationship of T2DM and cognitive decline is very intricate as some unforeseen underlying mechanism targeting neurodegeneration and vascular factors may also participate. Moreover, some studies have largely ignored the adjustment of the effect of risk variables in the analysis, however after adjusting the confounding effect in the backward step wise regression analyses in the present study, subjects having glucose levels >125 mmHg are at 1.73 times higher risk of developing impairment in neurocognition. This result is in agreement with several studies, [3, 22, [25] [26] [27] [28] [29] [30] however, few reports including Rancho Bernardo cohort study found no association of diabetes with neurocognitive decline. [31] Coker and Shumaker [25] compiled 32 studies which investigated the performance of neuropsychological tests in T2DM patients. Out of these, 67% (twenty studies) reported a positive association of diabetes with poor performance on neuropsychological tests. Another report has examined the relationship of impaired fasting glucose and neurocognition as the determinant of dementia in older women. [26] In a 4-year randomized trial of raloxifene use, it has been observed that after adjusting the effect of race, education, and co-existing depression, women show severe form of cognitive decline (P = 0.001). Similarly, another cross-sectional study on older men highlighted that higher insulin levels and glucose intolerance are significantly associated with lower MMSE scores. [27] Another study compiling the results of ten population-based reports on the association of T2DM and domain-specific neurocognition has revealed a substantial influence of diabetes on neurocognition impairment which may lead to the development of dementia. [22] In a longitudinal cohort study by Luchsinger et al., [3] diabetes is found to be a significant risk factor for all causes of mild cognitive impairment after adjustment for all risk covariates. The association of diabetes with nonamnestic mild cognitive impairment is attenuated after adjustment with vascular risk factors and socio-economic status. The age, gene/environment susceptibility in Reykjavik study has demonstrated that after adjusting the effects of demographic and health factors, persons with diabetes show poor performance in processing speed and executive functions. [4] The action to control cardiovascular risk in diabetes-memory in diabetes trial showed statistically significant association between A1C levels and four cognitive tests after adjusting age and other risk determinants. [28] In the investigation for the relationship of diabetes and cognitive impairment in Iranian population, Ebady et al. [29] documented that diabetes is significantly associated with lower MMSE scores (OR = 1.9, 95% CI: 1.01-3.6, P = 0.001), which is significantly correlated with duration and quality of diabetes. To understand the modifiers of cognitive function and brain structure in T2DM, it has been observed that subjects with T2DM have reduced hippocampal and prefrontal volumes, verbal declarative memory deficit, and impaired HPA axis feedback regulation. [30] A 20-year follow-up atherosclerosis risk in communities for cognitive change [32] has shown that midlife hypertension, especially higher SBP is highly associated with cognitive decline. Another report concluded that SBP and heart rate independently influence the development of cognitive decline, incident cognitive dysfunction, and cognitive deterioration in high-risk patients with atherosclerosis and diabetes. [33] In the present study also, diabetic subjects having >120 mmHg of SBP had 3.70 times higher risk of neurocognitive decline in comparison to nondiabetic subjects.
Another risk factor that independently influenced cognition in the present study is sedentary life style. T2DM patients living sedentary life style have 2-fold higher risk of neurocognitive impairment than their active counterparts. This finding is in agreement with other studies which have shown that sedentary life style is the hallmark for neurocognitive impairment. [34, 35] Duration of diabetes has been observed to influence neurocognition very strongly. Considerable derangements of neurocognition in T2DM patients, especially among older women have been examined. [36] In this longitudinal study, unfavorable cognitive performance has been shown in diabetic subjects over 4 years compared with subjects who had normal glucose levels. [37] It has been revealed that patients diagnosed for diabetes from the last 5 years perform poor for domain-specific cognition such as logical memory and word fluency in comparison to those who are diagnosed lately. [5] A report from Hyderabad, Telangana, India, shows that subjects having duration of diabetes >5 years show increased P300 latencies (cognitive dysfunction), a marker of speed of neural events related to attention and short-term memory. [38] Similarly, another study reported that negative correlation exists (r = −0.408, P = 0.001) between MMSE scores and duration of diabetes in Iranian population. [32] In the present study, diabetic subjects who have duration of diabetes >10 years are at 4.34 times higher risk of cognitive impairment.
Limitations
Some potential limitations of the present study may have influenced the results. First, MMSE scoring to identify neurocognition can be influenced by age and education. Although present study was well matched for these two variables (P > 0.05) and other tests involved for diagnosing cognitive decline show significant matching of reliability index (Cronbach's α = 0.82) with MMSE, residual confounding for timed elements of memory and executive functions may have remained to be exposed as MMSE is considered to be less sensitive for them. Second, notwithstanding our study attained considerable power to detect differences, the number of diabetic subjects according to gender in the present study are relatively less, so the implications need caution; more studies involving large cohorts are required to substantiate our key findings.
Conclusions
The present study shows that majority of the T2DM patients remain undiagnosed for neurocognition during the course of their life. Cognitive decline in diabetes is independently influenced by risk variables such as being a women, SBP >120 mmHg, sedentary life style, glucose levels >125 mg/dl, and duration of diabetes >10 years. Higher prevalence of cognitive decline in this region is alarming, and results of the present study suggest that every diabetic subject should be examined for cognition so that future imperative sequels of T2DM, especially neurodegeneration and vascular dementia may be tackled effectively.
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